Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
At what pace is the invasive aspergillosis therapeutics market growing, and what is its estimated value?
The invasive aspergillosis therapeutics market size has grown strongly in recent years. It will grow from $1.08 billion in 2024 to $1.14 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to the rise in the incidence of immunocompromised conditions, the increase in hospital-acquired fungal infections, increased diagnosis rates, the emergence of azole resistance, and the increase in healthcare spending.
The invasive aspergillosis therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.37 billion in 2029 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to the rising prevalence of chronic diseases, growing healthcare infrastructure in emerging economies, increasing use of immunosuppressants, rising awareness among healthcare professionals, and expansion of diagnostics to rural markets. Major trends in the forecast period include a shift towards combination therapies, the development of fungal vaccines, the adoption of monoclonal antibody therapies, the integration of telemedicine in treatment protocols, and the integration of genomics in treatment.
Get Your Free Sample of The Global Invasive Aspergillosis Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21211&type=smp
What are the top drivers to the rising demand in the invasive aspergillosis therapeutics market?
The rising prevalence of fungal infections is expected to propel the growth of the invasive aspergillosis therapeutics market going forward. Fungal infections refer to diseases caused by fungi invading tissues, often affecting skin, nails, or internal organs. The prevalence of fungal infections is growing due to increasing immunocompromised populations, climate change, antimicrobial resistance, and global travel exposure. Invasive aspergillosis therapeutics are helpful for fungal infections by utilizing antifungal agents like triazoles, echinocandins, and polyenes, which help inhibit fungal growth, reduce disease progression, and improve survival rates, making early diagnosis crucial for managing other invasive fungal infections with similar pathogenic mechanisms. For instance, in January 2024, according to the Center for Infectious Disease Research and Policy, a US-based public health company, in 2023, over 6.55 million people are affected by invasive fungal infections annually, leading to more than 3.75 million deaths, with 2.55 million directly attributable to these diseases, significantly higher than previous year estimates. Therefore, the rising prevalence of fungal infections is driving the growth of the invasive aspergillosis therapeutics market.
How is the invasive aspergillosis therapeutics market segmented?
The invasive aspergillosis therapeutics market covered in this report is segmented –
1) By Drug Class: Azoles, Echinocandins, Polyenes, Other Drug class
2) By Route Of Administration: Oral, Intravenous
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
Subsegments:
1) By Azoles: Triazoles, Imidazoles
2) By Echinocandins: Caspofungin, Micafungin, Anidulafungin
3) By Polyenes: Amphotericin B, Lipid Formulations Of Amphotericin B
4) By Other Drug Class: Allylamines, Pyrimidine Analogs
Order your report now for swift delivery
Who are the top competitors in the invasive aspergillosis therapeutics market?
Major companies operating in the invasive aspergillosis therapeutics market are Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline PLC, Gilead Sciences, Astellas Pharma Inc., Shionogi & Co. Ltd, Hikma Pharmaceuticals, Cipla Ltd., Mylan Pharmaceuticals Inc., Zambon SpA, Mayne Pharma Group Limited, Basilea Pharmaceutica International Ltd., Pulmocide Ltd., F2G Ltd., TFF Pharmaceuticals Inc., Hetero Healthcare, Eugia Pharma, SCYNEXIS Inc., PULMATRiX Inc., BioSpectrum India, Biosergen AB.
What significant trends should we anticipate in the invasive aspergillosis therapeutics market over the forecast period?
Major companies operating in the invasive aspergillosis therapeutics market are emphasizing effective treatments, including generic drugs, to improve accessibility, lower costs, and enhance patient outcomes. Generic drugs contain the same active ingredients, dosage, safety, strength, administration route, quality, and efficacy as brand-name counterparts but are generally more affordable. For instance, in September 2023, BDR Pharmaceutical, an India-based pharma company, announced the launch of its innovative generic product, Zisavel capsules, designed to treat invasive aspergillosis and mucormycosis. Zisavel belongs to the isavuconazole class of azole antifungals and provides a crucial therapeutic option for these serious fungal infections. The capsules are available in a 100 mg dosage and are positioned as the first-line treatment for both conditions. Priced at Rs. 7,992 for a pack of seven capsules, Zisavel is approximately one-third the cost of the current innovator therapy, making it a cost-effective alternative for patients.
Which regional trends are influencing the invasive aspergillosis therapeutics market, and which area dominates the industry?
North America was the largest region in the invasive aspergillosis therapeutics market in 2024. The regions covered in the invasive aspergillosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Invasive Aspergillosis Therapeutics Market Report 2025 Offer?
The invasive aspergillosis therapeutics market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Invasive aspergillosis therapeutics refers to treatments used to manage severe Aspergillus infections, primarily in immunocompromised patients. These include antifungal medications such as voriconazole, amphotericin B, and echinocandins, which target fungal growth and infection spread. Adjunctive therapies, such as immunomodulators and surgical interventions, may be considered in refractory cases.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21211
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
